Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) is frequently in the news for developments related to its stabilized hypochlorous acid (HOCl) products based on patented Microcyn technology. The company issues regular updates on product launches, regulatory milestones, distribution partnerships, and financial results, giving investors and industry observers insight into how its HOCl portfolio is being deployed in wound care, eye care, oral and nasal care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants.
News coverage often highlights Sonoma’s expansion into consumer and professional markets. Recent press releases describe HOCl-based diaper rash products for infants and children launched into large U.S. retailers, hypochlorous acid-based acne products placed in retail pharmacy chains in the United Kingdom, and a Microcyn-based facial spray listed under the FDA’s Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The company also reports on collaborations such as its HOCl wound cleanser manufactured for Medline Industries, LP for distribution into U.S. hospital systems and home healthcare channels.
Regulatory and recognition updates are another key theme. Sonoma has announced successful transition of its European products to the EU Medical Device Regulation (MDR), registrations with the MHRA in the United Kingdom, and multiple seals for Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel from organizations such as the National Psoriasis Foundation and the National Rosacea Society. Financial news includes quarterly and annual results, revenue trends by region, and non-GAAP metrics such as EBITDA loss.
By following the SNOA news feed, readers can monitor how Sonoma’s HOCl-based products are progressing through new markets, how its regulatory footprint is evolving, and how these developments are reflected in reported financial performance and corporate actions.
Sonoma Pharmaceuticals (Nasdaq:SNOA) has launched the MicrocynVS line of products specifically for veterinarians, aimed at addressing various animal health issues including wounds and infections. The products leverage patented Microcyn technology containing stabilized hypochlorous acid, enhancing healing processes in animals. A non-exclusive distribution agreement with DV Medical Supply has been established to roll out these products to over 700 veterinary offices across the U.S. MicrocynVS is expected to significantly improve veterinary care and reduce inventory costs for veterinarians.
Sonoma Pharmaceuticals (SNOA) reported Q4 2022 revenues of $2.3 million, a 7% increase from $2.2 million in Q4 2021. The net loss per share improved to $2.9 million, down 14% year-over-year. Operating expenses rose 20% to $3.2 million, primarily due to reconciliations related to the Rx dermatology divestiture. For the fiscal year, total revenue fell to $12.6 million, a $6 million decrease from $18.6 million in FY 2021. Cash reserves stand at $7.4 million, reflecting a strong balance sheet amid transitions toward profitability and growth.
Sonoma Pharmaceuticals (SNOA) announced that its Nanocyn hospital-grade disinfectant has been added to the U.S. Environmental Protection Agency’s List N, which includes COVID-19 disinfectants. This inclusion signifies extended approval for Nanocyn, which was initially approved for use as a disinfectant in April 2022. Additionally, Nanocyn achieved European Standard (EN) 17272 for Airborne Room Disinfection, enhancing its application in healthcare settings. The product has a short contact time of 30 seconds to eliminate viruses and is categorized as low toxicity by the EPA.
Sonoma Pharmaceuticals, Inc. (SNOA) announces EPA approval for Nanocyn®, a hospital-grade disinfectant developed with MicroSafe Group. Utilizing patented Microcyn® technology, Nanocyn® effectively reduces infection risk on hard surfaces, killing various bacteria and viruses, including norovirus, in just 30 seconds. The product, already distributed in Europe, the Middle East, and Australia, now has the potential to enter the U.S. market. With a low toxicity profile and no special handling requirements, Nanocyn® aims to enhance infection control in high-risk environments.
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) has launched Microdox®, a new urinary tract infection catheter and bladder rinse, in New Zealand, Australia, and South Africa. This innovative product utilizes Sonoma's patented Microcyn® Technology and is designed to treat and prevent urinary tract infections (UTIs) by effectively removing UTI-causing bacteria and biofilms. The solution is non-irritating and non-toxic, ready for immediate use through partners like Te Arai BioFarma and NuAngle. The company aims to improve patient quality of life and tackle antibiotic-resistant infections.
Sonoma Pharmaceuticals (SNOA) reported a 41% decline in revenue for Q3 2021, totaling $2.9 million, due to the termination of its low-margin contract with Invekra. Despite this, gross profit improved to 41% of revenues, up 1% year-over-year and 8% sequentially. The company reported a net loss of $(944,000) compared to $(626,000) in the prior year. Total operating expenses rose slightly by 1%. Cash reserves increased to $8.5 million, indicating a strengthened balance sheet.
Sonoma Pharmaceuticals (SNOA) has expanded its U.S. distribution network by partnering with Salus Medical for the distribution of Endocyn® root canal irrigant and Microcyn® products. Additionally, Sonoma entered a partnership with Anlicare International to distribute its oral and dental care products in China, where Anlicare will manage regulatory costs for exclusive distribution rights. Sonoma's Microcyn technology offers advanced antimicrobial properties for a variety of applications, enhancing its market presence in dental care.
Sonoma Pharmaceuticals, Inc. (SNOA) announces its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Amy Trombly and CFO Jerry Dvonch will present the company's business overview. Institutional investors can register for the virtual event through the provided link. Sonoma specializes in developing stabilized hypochlorous acid (HOCl) products for various healthcare applications, reducing infections and promoting healing. The company operates globally, distributing products in 54 countries.
Sonoma Pharmaceuticals (SNOA) reported its Q2 2021 financial results, showing revenues of $3.74 million, a 35% decline year-over-year, but a 2% increase from the previous quarter. The net loss improved to $(95,000) from $(1.1 million) in Q1. Gross profit was $1.24 million, a 33% margin, down from 43% a year ago. Operating expenses decreased by 5% year-over-year. The company raised $7.2 million through stock sales to support new product launches. Cash reserves stood at $8.4 million, indicating a strengthened balance sheet.
Sonoma Pharmaceuticals, Inc. (SNOA) and Dyamed Biotech Pte Ltd. announced an expanded partnership in Southeast Asia to enhance the reach of Sonoma's Microcyn® Technology. This partnership will cover Singapore, Malaysia, Indonesia, and Thailand, facilitating the introduction of several products including Dermacyn® for wound care, Ocucyn® for eye care, and Oracyn® for oral care. Dyamed plans new product launches in 2022, highlighting successful hospital usage in Singapore and Malaysia.